Product Pipeline
Innovative and diverse programs
Our pipeline covers both pharmaceutical and consumer product applications for disease treatment, disease interception and disease prevention.
Clinical program
Phase 1b/2a: MH002 - ulcerative colitis, ongoing expansion across gut inflammation.
Read More
Preclinical programs
Parkinson’s and metabolic diseases (co-development with IFF, formerly DuPont).
Discovery programs
Ongoing program in spondylarthritis and autoimmune conditions.
Targeting both the Pharma
and the OTC markets
By combining highly skilled scientists from different disciplines with an extensive in house technology platform, relevant market insights and sufficient financial means, MRM Health is in the unique position to exploit its expertise in gut physiology and microbiology for setting up a differentiating product development activity based on the use of live bacteria.
Contact us